Clinical Trials · NCT03495102
A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,842
- Start date
- Apr 2018
- Locations
- 208 sites, 16 countries
- Primary endpoint
- Change in Hemoglobin A1c (HbA1c) From Baseline